Sheila F Lumley, Jolynne Mokaya, Tongai G Maponga, Anna Kramvis, Geoffrey Dusheiko, William Irving, Marion Delphin, Khadija Said Mohammed, Louise O Downs, Elizabeth Waddilove, Motswedi Anderson, Collins Iwuji, Nokukhanya Msomi, Ponsiano Ocama, Saeed Hamid, Danjuma Adda, Rachel Halford, Kenneth Kabagambe, Kimberley S M Benschop, Seth Inzaule, Polin Chan, Margaret Alia Samson Paul, Kiyohiko Izumi, Tiara Nisa, Jean De Dieu Iragena, Amalia Girón-Callejas, Aboudou Raïmi Kpossou, Ganiyu Jamiyu, Omolara Emmanuel, Mahamadou Balkissa, Mamadou Keita, Nishi Prabdial-Sing, Alexander Martinez, Eleanor Namusoke Magongo, Yiming Shao, Omar Sued, Leandro Soares Sereno, Robert W Shafer, Olufunmilayo Lesi, Diana Faini, Philippa Easterbrook, Chris Duncombe, Michael R Jordan, Philippa C Matthews
{"title":"乙型肝炎病毒对核苷类似物治疗的耐药性：世卫组织就该领域的问题、挑战和路线图进行磋商。","authors":"Sheila F Lumley, Jolynne Mokaya, Tongai G Maponga, Anna Kramvis, Geoffrey Dusheiko, William Irving, Marion Delphin, Khadija Said Mohammed, Louise O Downs, Elizabeth Waddilove, Motswedi Anderson, Collins Iwuji, Nokukhanya Msomi, Ponsiano Ocama, Saeed Hamid, Danjuma Adda, Rachel Halford, Kenneth Kabagambe, Kimberley S M Benschop, Seth Inzaule, Polin Chan, Margaret Alia Samson Paul, Kiyohiko Izumi, Tiara Nisa, Jean De Dieu Iragena, Amalia Girón-Callejas, Aboudou Raïmi Kpossou, Ganiyu Jamiyu, Omolara Emmanuel, Mahamadou Balkissa, Mamadou Keita, Nishi Prabdial-Sing, Alexander Martinez, Eleanor Namusoke Magongo, Yiming Shao, Omar Sued, Leandro Soares Sereno, Robert W Shafer, Olufunmilayo Lesi, Diana Faini, Philippa Easterbrook, Chris Duncombe, Michael R Jordan, Philippa C Matthews","doi":"10.1016/j.lanmic.2025.101076","DOIUrl":null,"url":null,"abstract":"<p><p>In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101076"},"PeriodicalIF":20.9000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field.\",\"authors\":\"Sheila F Lumley, Jolynne Mokaya, Tongai G Maponga, Anna Kramvis, Geoffrey Dusheiko, William Irving, Marion Delphin, Khadija Said Mohammed, Louise O Downs, Elizabeth Waddilove, Motswedi Anderson, Collins Iwuji, Nokukhanya Msomi, Ponsiano Ocama, Saeed Hamid, Danjuma Adda, Rachel Halford, Kenneth Kabagambe, Kimberley S M Benschop, Seth Inzaule, Polin Chan, Margaret Alia Samson Paul, Kiyohiko Izumi, Tiara Nisa, Jean De Dieu Iragena, Amalia Girón-Callejas, Aboudou Raïmi Kpossou, Ganiyu Jamiyu, Omolara Emmanuel, Mahamadou Balkissa, Mamadou Keita, Nishi Prabdial-Sing, Alexander Martinez, Eleanor Namusoke Magongo, Yiming Shao, Omar Sued, Leandro Soares Sereno, Robert W Shafer, Olufunmilayo Lesi, Diana Faini, Philippa Easterbrook, Chris Duncombe, Michael R Jordan, Philippa C Matthews\",\"doi\":\"10.1016/j.lanmic.2025.101076\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.</p>\",\"PeriodicalId\":46633,\"journal\":{\"name\":\"Lancet Microbe\",\"volume\":\" \",\"pages\":\"101076\"},\"PeriodicalIF\":20.9000,\"publicationDate\":\"2025-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Microbe\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1016/j.lanmic.2025.101076\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Microbe","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.lanmic.2025.101076","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field.
In this Review, we summarise outputs from a multidisciplinary consultation convened by WHO between July 11 and 13, 2023, to discuss hepatitis B virus (HBV) drug resistance (HBVDR). Treatment of chronic HBV infection with highly effective nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the global goal of elimination of HBV infection as a public health threat. The risk of HBVDR as a threat to treatment outcomes is currently considered low from a public health perspective; however, drug resistance can influence individual outcomes, particularly among those who are treatment-experienced. We highlight the need to develop appropriate prevention, monitoring, and surveillance approaches for HBVDR, to support investment in the global scale-up of HBV diagnosis and treatment. Recommendations for the HBVDR field will ultimately be incorporated into a WHO integrated Global Action Plan for drug-resistant HIV, viral hepatitis, and priority sexually transmitted infections.
期刊介绍：
The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
